ResMed Inc (RMD) stock
Close on Nov 12, 2026Market cap $33.60BP/E 21.8Yield 1.00%
ResMed Inc grew revenue 9.0% to $5.73B over the twelve months to Sep 30, 2026. Operating income rose 8.5% to $1.89B, moving the operating margin from 33.2% to 33.0%. Free cash flow was $1.61B, down 9.0% from a year earlier. At the latest close the market valued the company at $33.60B, 21.8 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $33.60B
- P/E ratio
- 21.8
- Price to sales
- 5.86
- Price to book
- 5.65
- Dividend yield
- 1.00%
- Free cash flow yield
- 4.79%
Fundamentals
- Revenue
- $5.73B
- Net income
- $1.59B
- EPS, diluted
- $10.98
- Free cash flow
- $1.61B
- Book value per share
- $41.47
- Diluted shares
- 143M
Trading
- Next earnings
- Jan 28, 2027 (estimated, after the close)
- Previous close
- $238.53
- Open
- $238.78
- Day's range
- $237.83 – $243.45
- Volume
- 1,088,990
- Average volume (20 days)
- 1,510,455
- Index membership
- S&P 500, Russell 1000, Russell 3000
- Beta (5 years)
- 0.92
- 52-week range
- $180.26 – $277.67
- RSI (14 days)
- 51.8
- Volatility (1 year)
- 30.8%
- Relative volume
- 0.80×
- WACC
- 9.4%
On 2 of our idea lists: Quality compounders, Quality on sale
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2009, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | RMD | S&P 500 | Difference | RMD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1.8% | -2.7% | +4.5 pts | ||
| 3 months | +6.0% | -1.7% | +7.8 pts | ||
| Year to date | -0.0% | +11.9% | −11.9 pts | ||
| 1 year | -4.5% | +12.0% | −16.5 pts | ||
| 3 years | +70.8% | +78.2% | −7.4 pts | +19.5% | +21.2% |
| 5 years | -2.0% | +73.2% | −75.3 pts | -0.4% | +11.6% |
| 10 years | +343.4% | +309.6% | +33.7 pts | +16.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2012 to 2026 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases ResMed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
About ResMed
Surgical & Medical Instruments & Apparatus
ResMed Inc. develops digital health solutions, cloud-connected medical devices, and care management software platforms. The company operates through two business segments: Sleep and Breathing Health, and Residential Care Software. Its core offering includes continuous positive airway pressure systems, bilevel and adaptive servo-ventilation equipment, ventilators, diagnostic products, mask systems, and cloud applications like AirView and myAir. In addition, it provides residential care management platforms, including Brightree and MEDIFOX DAN. Its solutions serve individuals with sleep apnea and respiratory conditions, alongside clinicians, durable medical equipment suppliers, and residential healthcare organizations.
Company profile, executives and historyResMed stock: common questions
What is ResMed's stock price?
RMD closed at $238.89 on Nov 12, 2026, up 0.15% on the day. Over the past 52 weeks it traded between $180.26 and $277.67.
What is ResMed's market cap?
ResMed was worth $33.60B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is RMD's P/E ratio?
RMD trades at 21.8 times earnings, based on diluted earnings per share of $10.98 over the twelve months to Sep 30, 2026.
How much revenue does ResMed make?
ResMed reported revenue of $5.73B for the twelve months to Sep 30, 2026, up 9.0% from a year earlier.
Does ResMed pay a dividend?
Yes. ResMed paid $2.40 per share over the last twelve months, a yield of 1.00% at the latest price, and has raised its annual dividend 5 years in a row.
When does ResMed report earnings next?
ResMed is expected to report Q2 FY2027 results on Jan 28, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has RMD stock performed over the past year?
Including dividends, RMD returned -4.5% over the past year, against +12.0% for the S&P 500.
Who are ResMed's competitors?
Companies most similar to ResMed by business, industry and size include SOLV, BAX, DXCM, MMED, TFX.
See a number that looks wrong?